Minze Health Secures $5.3 Million to Advance Prescription Digital Therapeutics and U.S. Market Commercialization
Minze Health Secures $5.3 Million in Funding to Advance Digital Health Solutions for Urology Minze Health, a leader in digital health solutions tailored for urology, has successfully raised $5.3 million…
Modivcare and Tenovi Partner to Improve Respiratory Care with Hailie® Smart Inhalers
Modivcare Partners with Tenovi to Enhance Respiratory Care Using Adherium’s Hailie® Smart Inhalers Modivcare Inc., a prominent technology-enabled healthcare services company, has announced a partnership with Tenovi, a pioneer in…
Sage Therapeutics Restructures to Prioritize ZURZUVAE® Launch and Streamline Development Pipeline
Sage Therapeutics, Inc. (Nasdaq: SAGE) has unveiled a strategic reorganization initiative aimed at prioritizing the commercialization of ZURZUVAE® for postpartum depression while sharpening its focus on pipeline development, including the…
Marinus Pharma Shares Phase 3 RAISE Trial Results on Refractory Status Epilepticus at Neurocritical Care 2024
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a company focused on developing innovative therapies for seizure disorders, has shared new data from its Phase 3 RAISE trial on intravenous (IV) ganaxolone for…
AMIVAS Unveils Europe’s First Licensed Treatment for Severe Malaria
Artesunate AMIVAS, the first fully licensed treatment for severe malaria in Europe, is now available for purchase across Europe and the U.K. through Nordic Prime in Denmark. Approved by the…
Helfie AI Adds Healthcare Experts Antonin de Fougerolles and Cheryl Buxton to Board of Directors
Helfie AI, a global leader in mobile health technology, has strengthened its Board of Directors with the addition of two healthcare veterans. Antonin (Tony) de Fougerolles, PhD, a distinguished scientist…
Viatris Secures Global Licensing Deal with Lexicon for Sotagliflozin Outside U.S. and Europe
Viatris Signs Exclusive Licensing Deal with Lexicon for Sotagliflozin Outside U.S. and Europe PITTSBURGH, Oct. 16, 2024 /PRNewswire/ — Viatris Inc. (Nasdaq: VTRS) has reached an exclusive licensing agreement with…
Regional Study Shows Blood Biomarkers Can Predict Brain Amyloid Beta Accumulation
Shimadzu Corporation, Eisai Co., Ltd., Oita University, and the Usuki City Medical Association have demonstrated that blood biomarkers can effectively predict amyloid beta (Aβ) accumulation in the brain, a major…
Shionogi Showcases Global Study on Cefiderocol Highlighting High Clinical Response in Critically Ill Patients
Shionogi & Co., Ltd. recently presented findings at IDWeek 2024 from the PROVE study, the largest global real-world evidence study on cefiderocol (marketed as Fetroja®/Fetcroja®), a siderophore cephalosporin antibiotic for…
WuXi Biologics Earns Fourth Consecutive ESG Corporate Platinum Award from The Asset
WuXi Biologics (“WuXi Bio”) (2269.HK), a global leader in Contract Research, Development, and Manufacturing Organization (CRDMO), announced its fourth consecutive Platinum Award from The Asset ESG (Environmental, Social, and Governance)…
BeiGene Showcases Waldenström’s Macroglobulinemia Advances at IWWM 2024
BeiGene Showcases Promising Waldenström’s Macroglobulinemia Research at IWWM 2024 San Mateo, Calif. – BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology leader, announced its participation in the…
Alnylam Submits EMA Application for Vutrisiran in ATTR Amyloidosis Treatment
Alnylam Submits Type II Variation to EMA for Vutrisiran in ATTR Amyloidosis with Cardiomyopathy CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 16, 2024—Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced the submission of a Type II…